• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

SEOM 临床指南：静脉血栓栓塞症（VTE）和癌症（2023 年）。

SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023).

机构信息

Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.

Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

出版信息

Clin Transl Oncol. 2024 Nov;26(11):2877-2901. doi: 10.1007/s12094-024-03605-2. Epub 2024 Aug 7.

DOI:10.1007/s12094-024-03605-2
PMID:39110395
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11467034/
Abstract

The Spanish Society of Medical Oncology (SEOM) last published clinical guidelines on venous thromboembolism (VTE) and cancer in 2019, with a partial update in 2020. In this new update to the guidelines, SEOM seeks to incorporate recent evidence, based on a critical review of the literature, to provide practical current recommendations for the prophylactic and therapeutic management of VTE in patients with cancer. Special clinical situations whose management and/or choice of currently recommended therapeutic options (low-molecular-weight heparins [LMWHs] or direct-acting oral anticoagulants [DOACs]) is controversial are included.

摘要

西班牙肿瘤医学学会 (SEOM) 最后一次发布静脉血栓栓塞症 (VTE) 和癌症临床指南是在 2019 年，并于 2020 年进行了部分更新。在这些指南的最新更新中，SEOM 寻求结合最新证据，基于对文献的严格审查，为癌症患者 VTE 的预防和治疗管理提供实用的当前建议。本指南还纳入了一些特殊临床情况，这些情况下的管理和/或目前推荐的治疗方案（低分子肝素 [LMWHs] 或直接口服抗凝剂 [DOACs]）的选择存在争议。

相似文献

1
SEOM clinical guidelines on venous thromboembolism (VTE) and cancer (2023).SEOM 临床指南：静脉血栓栓塞症（VTE）和癌症（2023 年）。
Clin Transl Oncol. 2024 Nov;26(11):2877-2901. doi: 10.1007/s12094-024-03605-2. Epub 2024 Aug 7.
2
Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.癌症患者静脉血栓栓塞症长期治疗的抗凝治疗
Cochrane Database Syst Rev. 2018 Jun 19;6(6):CD006650. doi: 10.1002/14651858.CD006650.pub5.
3
Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants.静脉血栓栓塞症与癌症：直接口服抗凝剂的现状与未来。
Thromb Res. 2019 May;177:33-41. doi: 10.1016/j.thromres.2019.02.031. Epub 2019 Feb 27.
4
SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019).SEOM 临床指南：静脉血栓栓塞症（VTE）和癌症（2019 年）。
Clin Transl Oncol. 2020 Feb;22(2):171-186. doi: 10.1007/s12094-019-02263-z. Epub 2020 Jan 24.
5
Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism.直接口服抗凝剂与传统抗凝剂在静脉血栓栓塞症中的安全性。
J Thromb Thrombolysis. 2019 Oct;48(3):439-453. doi: 10.1007/s11239-019-01878-x.
6
Use of Direct Oral Anticoagulants for Treating Venous Thromboembolism in Patients With Cancer.直接口服抗凝剂在癌症患者静脉血栓栓塞症治疗中的应用。
J Natl Compr Canc Netw. 2018 May;16(5S):670-673. doi: 10.6004/jnccn.2018.0041.
7
Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.编辑精选 - 抗凝治疗癌症患者静脉血栓栓塞症的疗效和安全性的系统评价和荟萃分析。
Eur J Vasc Endovasc Surg. 2019 May;57(5):685-701. doi: 10.1016/j.ejvs.2018.11.004.
8
[Low-molecular-weight heparins for cancer-associated thromboembolism: What place in 2019?].[低分子量肝素用于癌症相关血栓栓塞：2019年的地位如何？]
Bull Cancer. 2020 Feb;107(2):224-233. doi: 10.1016/j.bulcan.2019.11.007. Epub 2020 Jan 28.
9
Cancer and venous thromboembolism: prevention, treatment and survival.癌症与静脉血栓栓塞：预防、治疗及生存
J Thromb Thrombolysis. 2008 Feb;25(1):33-6. doi: 10.1007/s11239-007-0102-0. Epub 2007 Sep 29.
10
Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis.直接口服抗凝剂（DOACs）与传统抗凝治疗癌症相关静脉血栓栓塞症的疗效和安全性比较：一项回顾性分析。
Thromb Res. 2017 Feb;150:86-89. doi: 10.1016/j.thromres.2016.12.016. Epub 2016 Dec 22.

引用本文的文献

1
Retrospective Observational Study on Diagnosis and Treatment Trends of DVT in Japan: Japanese Vein Study XXVI.日本深静脉血栓形成诊断与治疗趋势的回顾性观察研究：日本静脉研究XXVI
Ann Vasc Dis. 2025;18(1). doi: 10.3400/avd.oa.25-00061. Epub 2025 Aug 14.
2
A Comprehensive Review of Catheter-Related Thrombosis.导管相关血栓形成的综合综述
J Clin Med. 2024 Dec 21;13(24):7818. doi: 10.3390/jcm13247818.

本文引用的文献

1
Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer.癌症患者轻度血小板减少症对出血和复发血栓的影响。
Haematologica. 2024 Jun 1;109(6):1849-1856. doi: 10.3324/haematol.2023.284192.
2
Acute venous thromboembolism in patients with brain cancer: clinical course.脑癌患者的急性静脉血栓栓塞：临床病程
Res Pract Thromb Haemost. 2023 Aug 20;7(6):102172. doi: 10.1016/j.rpth.2023.102172. eCollection 2023 Aug.
3
Risk-Directed Ambulatory Thromboprophylaxis in Lung and Gastrointestinal Cancers: The TARGET-TP Randomized Clinical Trial.风险导向的肺癌和胃肠道癌门诊血栓预防：TARGET-TP 随机临床试验。
JAMA Oncol. 2023 Nov 1;9(11):1536-1545. doi: 10.1001/jamaoncol.2023.3634.
4
Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial.依度沙班治疗癌症合并单纯远端深静脉血栓患者 12 个月与 3 个月的疗效比较（ONCO DVT 研究）：一项开放标签、多中心、随机临床试验。
Circulation. 2023 Nov 21;148(21):1665-1676. doi: 10.1161/CIRCULATIONAHA.123.066360. Epub 2023 Aug 28.
5
A Novel Risk Prediction Score for Clinically Significant Bleeding in Patients Anticoagulated for Venous Thromboembolism with Active Cancer.一种新型风险预测评分系统，用于预测伴有活动性癌症的静脉血栓栓塞症抗凝患者的临床显著出血风险。
Thromb Haemost. 2024 Apr;124(4):324-336. doi: 10.1055/a-2145-7238. Epub 2023 Aug 1.
6
Risk of intracranial hemorrhage with direct oral anticoagulation versus low molecular weight heparin in the treatment of brain tumor-associated venous thromboembolism: A meta-analysis.直接口服抗凝剂与低分子肝素治疗脑肿瘤相关静脉血栓栓塞症的颅内出血风险：一项荟萃分析。
J Stroke Cerebrovasc Dis. 2023 Aug;32(8):107243. doi: 10.1016/j.jstrokecerebrovasdis.2023.107243. Epub 2023 Jul 4.
7
Development of a predictive model of venous thromboembolism recurrence in anticoagulated cancer patients using machine learning.利用机器学习开发抗凝癌症患者静脉血栓栓塞复发的预测模型。
Thromb Res. 2023 Aug;228:181-188. doi: 10.1016/j.thromres.2023.06.015. Epub 2023 Jun 16.
8
Comparison of long-term complications in cancer patients with incidental and acute symptomatic venous thromboembolism.癌症患者伴偶然发生和急性症状性静脉血栓栓塞的长期并发症比较。
Front Cardiovasc Med. 2023 May 19;10:1118385. doi: 10.3389/fcvm.2023.1118385. eCollection 2023.
9
Direct Oral Anticoagulants vs Low-Molecular-Weight Heparin and Recurrent VTE in Patients With Cancer: A Randomized Clinical Trial.直接口服抗凝剂与低分子肝素在癌症患者中的疗效比较：一项随机临床试验。
JAMA. 2023 Jun 13;329(22):1924-1933. doi: 10.1001/jama.2023.7843.
10
Anticoagulation management and related outcomes in patients with cancer-associated thrombosis and thrombocytopenia: A systematic review and meta-analysis.癌症相关血栓形成和血小板减少症患者的抗凝管理及相关结局：系统评价和荟萃分析。
Thromb Res. 2023 Jul;227:8-16. doi: 10.1016/j.thromres.2023.05.012. Epub 2023 May 11.